BBOT Q4 2023 Earnings — BridgeBio Oncology Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BBOTBridgeBio Oncology Therapeutics Inc.

$820M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$41,692

Net Income

-$41,692

EPS (Diluted)

$-0.00

Cash Flow

Operating Cash Flow

$0

Free Cash Flow

$0

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$332,894

Total Liabilities

$396,463

Stockholders' Equity

-$63,569

Cash & Equivalents

$0

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$41,692	-$3,520	-1084.4%
Net Income	-$41,692	-$3,520	-1084.4%